Daito Pharmaceutical Company Limited operates within the Medicinals and botanicals sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Daito Pharmaceutical Company Limited with three other
companies in this sector in Japan:
Fuji Pharma Company Limited
sales of 37.91 billion Japanese Yen [US$338.53 million]
of which 100%
was Pharmaceutical Business),
JCR Pharmaceuticals Co., Ltd.
(20.59 billion Japanese Yen [US$183.90 million]
of which 98%
was Pharmaceutical Business), and
Koa Shoji Holdings Co Ltd
(14.83 billion Japanese Yen [US$132.39 million]
of which 76%
was Drug substance sales business).
During the year ended May of 2018, sales at
Daito Pharmaceutical Company Limited were ¥39.88 billion (US$356.09 million).
increase of 5.0%
versus 2017, when the company's sales were ¥37.98 billion.
This was the fifth consecutive year of sales increases at Daito Pharmaceutical Company Limited
(and since 2013, sales have increased a total of 38%).
Sales of Formulation saw an increase
that was more than double the company's growth rate: sales were up
21.7% in 2018, from
¥15.37 billion to ¥18.71 billion.
Not all segments of Daito Pharmaceutical Company Limited experienced an increase in sales in 2018:
sales of Health Food Other fell 8.1% to ¥320.78 million.
(However, this segment's sales were only a very small portion of the company's overall sales).
Daito Pharmaceutical Company Limited also experienced decreases in sales in
Drug Substance (down 6.4% to ¥20.85 billion)